Curis shares surge 13.11% after-hours on Q1 2025 clinical trial progress and positive regulatory feedback.

Curis (NASDAQ:CRIS) surged 13.11% in after-hours trading following a series of positive developments highlighted in its Q1 2025 business update. The company reported expanded patient enrollment in lymphoma and AML trials for its drug candidate emavusertib, signaling progress toward potential accelerated regulatory approval. Analysts at TipRanks and MarketBeat cited strategic clinical advancements and favorable regulatory feedback as key drivers, while the appointment of a new Chief Medical Officer reinforced leadership strength. Despite missing Q1 2025 earnings estimates, the stock reacted positively to the emphasis on therapeutic pipeline progress and long-term growth prospects. Recent coverage from MSN and Yahoo Finance underscored the company’s focus on IRAK4 inhibitor development and enrollment timelines targeting 12–18 months for pivotal trials, aligning with a revised buy rating from Truist Financial and Cantor Fitzgerald. These factors collectively fueled investor optimism in after-hours trading.